New research reveals that people who stop using popular GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise regimens.
Findings released in a prominent medical journal demonstrates that while obese individuals often shed about a fifth of their total mass while on the medication, the mass comes back at an average rate of 0.8 kg per month once they quit.
"People buying these treatments must be cognizant of the potential of quick weight regain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to original mass in about one and a half years.
Analyzing Approaches
The research, which looked at dozens of trials involving over 9,000 of participants, compared the effects of the injectable medications with conventional dieting.
The team point out that people who shed pounds through lifestyle changes alone generally have a less rapid weight regain—perhaps 100 grams monthly—post-intervention.
Explaining the Fast Rebound
Nutrition scientists believe the mode of action of the drugs is key to understanding the amplified regain.
GLP-1 drugs mimic a body's own chemical called GLP-1, which helps regulate appetite.
"Long-term administration of GLP-1 concentrations far above than normal may cause the system to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement results in appetite is unsuppressed, making binge eating a significant risk."
A Chronic Disease?
Health authorities suggest the jabs for people with weight-linked medical conditions, alongside prescribed lifestyle changes.
Many experts argue that, given the significant potential of relapse, the treatment should be considered ongoing.
This perspective is reinforced by pharmaceutical companies, who state that the results "highlight the long-term character of excess weight," similar to managing diseases like diabetes.
Patient Accounts
People who have stopped the medication report a powerful resurgence of appetite.
"I experienced a switch activating and I was suddenly starving," said an individual.
This challenge is compounded if users have not developed sustainable lifestyle or habit modifications during therapy.
Significant Interest
Survey data suggest that a significant number of people in the UK have tried these injections in the past year, with desire being substantial.
- Adoption is more common among women compared to males.
- The 40s and 50s demographic shows the highest usage rates.
- Many access the medications through private healthcare rather than public health services.
In conclusion, researchers stress that while these medications are powerful agents for weight loss, they are not a permanent solution and long-term success hinges on combined lifestyle support.
